Acebutolol
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Acebutolol: From Hypertension to Malignant Renovascular Hypertension
One-Sentence Summary
Acebutolol is a cardioselective beta-blocker originally used to treat hypertension. The TxGNN model predicts it may be effective for malignant renovascular hypertension, but there are 0 registered clinical trials and only 1 publication (a 1975 open-label study of general hypertension) supporting this direction. This is largely an extension of the existing indication rather than true repurposing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension (hypertensive disorder); the Singapore licence records contain no indication text, so this comes from the knowledge graph |
| Predicted New Indication | Malignant renovascular hypertension |
| TxGNN Prediction Score | 99.10% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, acebutolol is a cardioselective beta-1 blocker with intrinsic sympathomimetic activity. Its efficacy in hypertension is established. Beta blockade reduces renin release, which is relevant to renovascular hypertension, where renin-driven mechanisms play a major role.
The relationship between the original and the new indication is very close, since both are forms of high blood pressure. The high TxGNN score probably reflects this similarity to the known hypertension indication rather than a new mechanism. Malignant hypertension usually requires urgent parenteral therapy, so oral acebutolol would not be a first-line choice.
Other predictions in the set are weaker. Pulmonary hypertension, Braddock syndrome and chronic pulmonary heart disease lack clinical rationale, and beta blockers may be harmful in right heart disease. Glaucoma has a class-level rationale only with topical beta blockers. Atrial flutter is the most credible alternative (L3, 3 studies, class II antiarrhythmic activity), but beta blockers are already standard for rate control there, so novelty is limited.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 768911 | 1975 | Clinical study (open-label) | La Nouvelle presse medicale | 50 hypertensive patients treated for one year with acebutolol, alone or combined; results good or moderate in 74%, failure in 26%; well tolerated. Not specific to malignant renovascular disease |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN08621P | APO-ACEBUTOLOL TABLET 100 mg | Film-coated tablet | Not stated in the licence record |
| SIN08620P | APO-ACEBUTOLOL TABLET 200 mg | Film-coated tablet | Not stated in the licence record |
| SIN08636P | APO-ACEBUTOLOL TABLET 400 mg | Film-coated tablet | Not stated in the licence record |
All three are single-ingredient oral products from Apotex Inc and are currently valid.
Safety Considerations
- Contraindications suggested by the knowledge graph (not label text): asthma (including allergic and intrinsic), pulmonary emphysema, atrioventricular block, sick sinus syndrome, peripheral vascular disease or arterial disease, diabetes mellitus and diabetic ketoacidosis, myasthenia gravis, pheochromocytoma and related adrenal tumours, kidney disease, liver disease, gallbladder disease, psoriasis, and anxiety or dysthymic disorders.
- Drug Interactions: 100 interactions were identified; the 20 reviewed here were mostly Moderate or Minor.
- Moderate: antidiabetic agents (acetohexamide, chlorpropamide, canagliflozin, dapagliflozin), corticosteroids (betamethasone, budesonide), calcium salts, atropine, clidinium, bupropion and cimetidine.
- Minor: aluminium hydroxide, acetylsalicylic acid and attapulgite.
Please also refer to the package insert, since label warnings and contraindications were not available for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for malignant renovascular hypertension is limited to a single 1975 open-label study of general hypertension, with no registered trials. The high score mainly reflects the drug's existing hypertension indication, and acute malignant hypertension is normally managed with parenteral therapy.
To proceed, the following is needed:
- The Singapore package insert, including warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data (for example from DrugBank)
- Disease-specific clinical evidence in renovascular or malignant hypertension
- Consideration of atrial flutter or supraventricular arrhythmia prevention as a more credible research question, with review of the 1985-1986 post-bypass studies to confirm design and effect size
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.